Accelrys marks Q4 growth as buyouts weigh on bottom line

Accelrys ($ACCL) touted revenue growth for the fourth quarter of 2012, a year in which the company stayed active on the M&A front and advanced scientific software products for biopharma and other customers.

Results were revealed late in the afternoon on Tuesday, Feb. 26. The company's shares were off less than 1% to $9.45 per share late in the morning on Feb. 27. 

Company CEO Max Carnecchia has kept a steady pace of buyouts over the past several years to help fuel growth at the San Diego-based company, most notably with its 2010 merger with electronic lab notebook provider Symyx. Yet the merger and other acquisitions, while beefing up revenue, have obvious costs.

The company reported a GAAP net loss of $8.2 million, or down $0.15 per share, in the fourth quarter of 2012 compared to net income of $14.2 million, or $0.19 per share, in the same quarter a year earlier, with the business impacted by costs associated with the $30 million cash purchase of Aegis Analytical in October 2012 and other expenses. Yet the company's revenue for the quarter jumped 11% to $44.2 million. 

A major theme for Accelrys has been to expand its offerings from research to the realm of commercialization, covering a broader part of the development cycle for new drugs and other science-based products. And the company has sought to integrate newly purchased and existing tools to provide customers with a more complete offering. Many of its products, including its electronic lab notebooks, compete directly with a rival business unit at PerkinElmer ($PKI).

"We are pleased with our performance in both 2012 and against the three-year plan we developed for our business following our 2010 merger with Symyx," Carnecchia said in a statement. "We achieved both market momentum and acknowledgment of our position as the leading provider of scientific innovation lifecycle management software."

For 2013, Accelrys rolled out a full-year non-GAAP revenue projection between $185 million and $190 million, up from non-GAAP revenue of $174.3 million in 2012.

- here's the release
- see the transcript of the earnings call on Tuesday from Seeking Alpha

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.